AI Article Synopsis
Article Abstract
Recombinant Human Erythropoietin (EPO) is extensively used for anemia in renal failure patients. It is normally safe and effective, improving symptoms of anemia. We report here a case of renal anemia in a patient undergoing peritoneal dialysis (PD) for end stage renal failure from renovascular disease. He initially responded well to Epoetin alpha (Eprex) but subsequently developed EPO antibodies and pure red cell aplasia (PRCA), becoming blood transfusion dependent. Subsequently, he responded to Darbepoetin alpha (Aranesp), without any complications in the presence of persisting EPO antibodies. This positive response, which restored hemoglobin values to normal, occurred despite general belief that any form of EPO will cross-react to EPO antibodies. This is the first case report where PRCA with EPO antibodies responded well to another EPO preparation without intervention from immunosuppression therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.ASN.0000135056.81056.A4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrated SegFlow, µSIA, and UPLC for Online Sialic Acid Quantitation of Glycoproteins Directly from Bioreactors.
Eng Life Sci
January 2025
Analytical Development & Analytical Attribute Science in Biologics Bristol Myers Squibb Devens Massachusetts USA.
This study emphasizes the critical importance of closely monitoring and controlling the sialic acid content in therapeutic glycoproteins, including EPO, interferon-γ, Orencia, Enbrel, and others, as the level of sialylation directly impacts their pharmacokinetics (PK), immunogenicity, potency, and overall clinical performance due to its influence on protein clearance via hepatic asialoglycoprotein receptors (ASGPR). The ASGPR recognizes and binds to glycoproteins exposed to terminal galactose or N-acetylgalactosamine residues, leading to receptor-mediated endocytosis. Recent studies have demonstrated that sialylation of O-linked glycan plays a role in protecting against macrophage galactose lectin (MGL)-mediated clearance.
View Article and Find Full Text PDFThe spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer.
Nat Commun
January 2025
MultiplexDX, s.r.o., Comenius University Science Park, Bratislava, Slovakia.
Current assays fail to address breast cancer's complex biology and accurately predict treatment response. On a retrospective cohort of 1082 female breast tissues, we develop and validate mFISHseq, which integrates multiplexed RNA fluorescent in situ hybridization with RNA-sequencing, guided by laser capture microdissection. This technique ensures tumor purity, unbiased whole transcriptome profiling, and explicitly quantifies intratumoral heterogeneity.
View Article and Find Full Text PDFStudy on Internal Standards Applicable to the Detection of Recombinant Erythropoietin.
Drug Test Anal
December 2024
Beijing Anti-Doping Laboratory, Beijing Sport University, Beijing, China.
Article Synopsis
- The discovery of the c.577del variant in the EPO gene has complicated testing for recombinant erythropoietin (rEPO), making detection more challenging.
- Researchers developed a new confirmation method that combines reverse-normal immunopurification, western blotting (WB), and SAR-PAGE to effectively identify both the EPO variant (VAR-EPO) and rEPO using specific antibodies.
- An internal standard (IS) made from VAR-EPO modified with polyethylene glycol (PEG) was created and shown to effectively monitor rEPO detection in urine samples, ensuring reliable doping analysis results.
Efficient Neutralizing Antibodies Induction by Human Parvovirus B19 Epitope-Presenting Protein Nanoparticles.
Microbiol Immunol
January 2025
Department of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, Hirosaki, Japan.
Human parvovirus B19 (B19V) causes fetal hydrops in pregnant women. Despite the significant impact of this virus, effective vaccines remain unclear. In this study, we successfully engineered B19V protein nanoparticles by fusing the N-terminal receptor-binding domain corresponding to 5-80 amino acids of VP1 with two distinct types of self-assembling protein nanoparticles.
View Article and Find Full Text PDFContext-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity.
Cell Rep
October 2024
Australian Centre for Blood Diseases, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia. Electronic address:
T cell surface CTLA4 sequesters the costimulatory ligands CD80 and CD86 on antigen-presenting cells (APCs) to prevent autoimmunity. Therapeutic immunosuppression by recombinant CTLA4-immunoglobulin (Ig) fusion proteins, including abatacept, is also attributed to CD80/CD86 blockade. Recent studies show that CTLA4-Ig binding to APC surface cis-CD80:PD-L1 complexes can release the inhibitory ligand PD-L1, but whether this contributes to T cell inhibition remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!